Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CT-radiomics and clinical risk scores for response and overall survival prognostication in TACE HCC patients.
Bernatz S, Elenberger O, Ackermann J, Lenga L, Martin SS, Scholtz JE, Koch V, Grünewald LD, Herrmann Y, Kinzler MN, Stehle A, Koch I, Zeuzem S, Bankov K, Doering C, Reis H, Flinner N, Schulze F, Wild PJ, Hammerstingl R, Eichler K, Gruber-Rouh T, Vogl TJ, Dos Santos DP, Mahmoudi S. Bernatz S, et al. Among authors: stehle a. Sci Rep. 2023 Jan 11;13(1):533. doi: 10.1038/s41598-023-27714-0. Sci Rep. 2023. PMID: 36631548 Free PMC article.
Computed Tomography Radiomics to Differentiate Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma.
Mahmoudi S, Bernatz S, Ackermann J, Koch V, Dos Santos DP, Grünewald LD, Yel I, Martin SS, Scholtz JE, Stehle A, Walter D, Zeuzem S, Wild PJ, Vogl TJ, Kinzler MN. Mahmoudi S, et al. Among authors: stehle a. Clin Oncol (R Coll Radiol). 2023 May;35(5):e312-e318. doi: 10.1016/j.clon.2023.01.018. Epub 2023 Feb 1. Clin Oncol (R Coll Radiol). 2023. PMID: 36804153
CXCL1 and CXCL6 Are Potential Predictors for HCC Response to TACE.
Kinzler MN, Bankov K, Bein J, Döring C, Schulze F, Reis H, Mahmoudi S, Koch V, Grünewald LD, Stehle A, Walter D, Finkelmeier F, Zeuzem S, Wild PJ, Vogl TJ, Bernatz S. Kinzler MN, et al. Among authors: stehle a. Curr Oncol. 2023 Mar 20;30(3):3516-3528. doi: 10.3390/curroncol30030267. Curr Oncol. 2023. PMID: 36975480 Free PMC article.
Small duct and large duct type intrahepatic cholangiocarcinoma reveal distinct patterns of immune signatures.
Bernatz S, Schulze F, Bein J, Bankov K, Mahmoudi S, Grünewald LD, Koch V, Stehle A, Schnitzbauer AA, Walter D, Finkelmeier F, Zeuzem S, Vogl TJ, Wild PJ, Kinzler MN. Bernatz S, et al. Among authors: stehle a. J Cancer Res Clin Oncol. 2024 Jul 22;150(7):357. doi: 10.1007/s00432-024-05888-y. J Cancer Res Clin Oncol. 2024. PMID: 39034327 Free PMC article.
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Fürstenau M, Kater AP, Robrecht S, von Tresckow J, Zhang C, Gregor M, Thornton P, Staber PB, Tadmor T, Lindström V, Juliusson G, Janssens A, Levin MD, da Cunha-Bang C, Schneider C, Goldschmidt N, Vandenberghe E, Rossi D, Benz R, Nösslinger T, Heintel D, Poulsen CB, Christiansen I, Frederiksen H, Enggaard L, Posthuma EFM, Issa DE, Visser HPJ, Bellido M, Kutsch N, Dürig J, Stehle A, Vöhringer M, Böttcher S, Schulte C, Simon F, Fink AM, Fischer K, Holmes EE, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Stilgenbauer S, Hallek M, Niemann CU, Eichhorst B. Fürstenau M, et al. Among authors: stehle a. Lancet Oncol. 2024 Jun;25(6):744-759. doi: 10.1016/S1470-2045(24)00196-7. Lancet Oncol. 2024. PMID: 38821083 Free article. Clinical Trial.
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, Staber PB, Tadmor T, Lindström V, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schöttker B, Nösslinger T, Janssens A, Christiansen I, Baumann M, Frederiksen H, van der Klift M, Jäger U, Leys MBL, Hoogendoorn M, Lotfi K, Hebart H, Gaska T, Koene H, Enggaard L, Goede J, Regelink JC, Widmer A, Simon F, De Silva N, Fink AM, Bahlo J, Fischer K, Wendtner CM, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Levin MD, van Oers M, Geisler C, Stilgenbauer S, Hallek M; GCLLSG, the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and Cancer Trials Ireland. Eichhorst B, et al. N Engl J Med. 2023 May 11;388(19):1739-1754. doi: 10.1056/NEJMoa2213093. N Engl J Med. 2023. PMID: 37163621 Clinical Trial.
16 results